Ostilox
Loading...Ostilox Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans.
For oral use in dogs only.
As with any NSAID all dogs should undergo a thorough history and physical examination before the initiation of NSAID therapy. Appropriate laboratory testing to establish hematological and serum biochemical baseline data is recommended prior to and periodically during administration. Owner should be advised to observe their dog for signs of potential drug toxicity and be given a client information sheet about OstiLox.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
OstiLox Oral Suspension is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.
History
There is currently no drug history available for this drug.
Other Information
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class. Each milliliter of OstiLox™ Oral Suspension contains meloxicam equivalent to 1.5 milligrams and sodium benzoate (1.5 milligrams) as a preservative. The chemical name for Meloxicam is 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carbox-amide-1, 1-dioxide. The formulation is a yellowish viscous suspension.
Sources
Ostilox Manufacturers
-
Mwi/vetone
![Ostilox (Meloxicam) Suspension [Mwi/vetone]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Ostilox | Mwi/vetone
Always provide client information sheet with prescription. Carefully consider the potential benefits and risk of OstiLox Oral Suspension and other treatment options before deciding to use OstiLox Oral Suspension. Use the lowest effective dose for the shortest duration consistent with individual response. OstiLox Oral Suspension should be administered initially at 0.09 mg/lb (0.2 mg/kg) body weight only on the first day of treatment. For all treatments after day 1, OstiLox Oral Suspension should be administered once daily at a dose of 0.045 mg/lb (0.1 mg/ kg). The syringes are calibrated to deliver the daily maintenance dose in lbs. Because the first dose (0.2 mg/kg) is two times the amount of the daily maintenance dose (0.1 mg/kg), two syringes containing the 0.1 mg/kg dose should be administered at the first dose.
-
Mwi/vetone
Ostilox | Mwi/vetone
Carefully consider the potential benefits and risk of OstiLox™ and other treatment options before deciding to use OstiLox™. Use the lowest effective dose for the shortest duration consistent with individual response.
Dogs: OstiLox™ 5 mg/mL Solution for Injection should be administered initially as a single dose at 0.09 mg/lb (0.2 mg/kg) body weight intravenously (IV) or subcutaneously (SQ), followed, after 24 hours, by meloxicam oral suspension at the daily dose of 0.045 mg/lb (0.1 mg/kg) body weight, either mixed with food or placed directly in the mouth.
Carefully consider the potential benefits and risk of OstiLox™ and other treatment options before deciding to use OstiLox™. Use the lowest effective dose for the shortest duration consistent with individual response.
Cats: Administer a single, one-time subcutaneous dose of OstiLox™ 5 mg/mL Solution for Injection to cats at a dose of 0.14 mg/lb (0.3 mg/kg) body weight. Use of additional meloxicam or other NSAIDs is contraindicated. (See Contraindications). To ensure accuracy of dosing, the use of a 1 mL graduated syringe is recommended.
![Ostilox (Meloxicam) Solution [Mwi/vetone]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=88df74f2-853c-433f-a398-a3bc60b3e984&name=ost00-0000-03.jpg)
Login To Your Free Account